HOPA '24, Site Agnositc T-DXd, & ALINA
Apr 11, 2024•14 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.
Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.
Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.
For the best experience, listen in Metacast app for iOS or Android